Rocke Tonie E, Kingstad-Bakke Brock, Berlier Willy, Osorio Jorge E
National Wildlife Health Center, U.S. Geological Survey, 6006 Schroeder Rd., Madison, WI 53711, USA.
Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, WI 53706, USA.
Vaccines (Basel). 2014 Oct 27;2(4):772-84. doi: 10.3390/vaccines2040772.
In previous studies, we demonstrated in mice and prairie dogs that simultaneous administration of two recombinant raccoon poxviruses (rRCN) expressing Yersinia pestis antigens (F1 and V307-a truncated version of the V protein) provided superior protection against plague challenge compared to individual single antigen constructs. To reduce costs of vaccine production and facilitate implementation of a sylvatic plague vaccine (SPV) control program for prairie dogs, a dual antigen construct is more desirable. Here we report the construction and characterization of a novel RCN-vectored vaccine that simultaneously expresses both F1 and V307 antigens. This dual antigen vaccine provided similar levels of protection against plague in both mice and prairie dogs as compared to simultaneous administration of the two single antigen constructs and was also shown to protect mice against an F1 negative strain of Y. pestis. The equivalent safety, immunogenicity and efficacy profile of the dual RCN-F1/V307 construct warrants further evaluation in field efficacy studies in sylvatic plague endemic areas.
在先前的研究中，我们在小鼠和草原犬鼠身上证明，与单个单抗原构建体相比，同时给予两种表达鼠疫耶尔森菌抗原（F1和V307——V蛋白的截短版本）的重组浣熊痘病毒（rRCN）能提供更好的鼠疫攻击保护。为了降低疫苗生产成本并促进草原犬鼠野生型鼠疫疫苗（SPV）控制计划的实施，双抗原构建体更具优势。在此，我们报告了一种新型RCN载体疫苗的构建和特性，该疫苗同时表达F1和V307抗原。与同时给予两种单抗原构建体相比，这种双抗原疫苗在小鼠和草原犬鼠中提供了相似水平的鼠疫保护，并且还显示出能保护小鼠免受F1阴性鼠疫耶尔森菌菌株的侵害。双RCN - F1/V307构建体等效的安全性、免疫原性和功效概况值得在野生型鼠疫流行地区进行进一步的现场功效研究评估。
